ETF Holdings Breakdown of REPL

REPL institutional holdings

The following institutional investment holdings of REPL have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	40,373	USD 364,972 -1.0%	9.04
2025-11-12	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	10,063 -0.3%	USD 90,970 -1.3%	9.04
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	51,501	USD 465,569	9.04
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	51,501 0.3%	USD 465,569 -0.7%	9.04
2025-11-12	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	553	USD 4,999 -1.0%	9.04
Total =		153,991	USD 1,392,079

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with REPL

HC Wainwright Reaffirms “Neutral” Rating for Replimune Group (NASDAQ:REPL)

Replimune Group (NASDAQ:REPL – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. Several other equities analysts have also recently commented on REPL. Barclays cut shares of Replimune Group from an “overweight” rating to an “equal weight” rating and dropped their target […] - 2025-09-10 03:00:56

Zurcher Kantonalbank Zurich Cantonalbank Purchases 5,876 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 106.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,410 shares of the company’s stock after purchasing an additional 5,876 shares during the period. […] - 2025-08-11 05:32:47

Wednesday's ETF Movers: XBI, OIH

In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 1.8% on the day. Components of that ETF showing particular strength include shares of Replimune Group, up about 104.8% and shares of Biohaven, up about 18.9% on the day. And underperfor - 2025-07-30 14:51:58

Replimune Group, Inc. (NASDAQ:REPL) Receives $21.00 Average PT from Analysts

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has been assigned a consensus recommendation of “Hold” from the twelve brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have issued a buy rating and one has given […] - 2025-07-25 05:48:57

Replimune Group (NASDAQ:REPL) Hits New 52-Week Low After Analyst Downgrade

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price hit a new 52-week low on Tuesday after Barclays downgraded the stock from an overweight rating to an equal weight rating. Barclays now has a $3.00 price target on the stock, down from their previous price target of $17.00. Replimune Group traded as low as […] - 2025-07-24 04:24:56

Pre-Market Most Active for Jul 22, 2025 : OPEN, TSLL, REPL, SQQQ, OSCR, NVDA, QS, RXRX, BBAI, JOBY, NIO, CVX

The NASDAQ 100 Pre-Market Indicator is down -5.34 to 23,174.72. The total Pre-Market volume is currently 168,215,532 shares traded.The following are the most active stocks for the pre-market session: Opendoor Technologies Inc (OPEN) is +0.62 at $3.83, with 67,855,698 shares trad - 2025-07-22 09:29:55

Replimune Group (NASDAQ:REPL) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Replimune Group (NASDAQ:REPL – Get Free Report) had its target price increased by research analysts at JPMorgan Chase & Co. from $16.00 to $19.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 52.00% […] - 2025-07-18 05:05:13

Replimune Group (NASDAQ:REPL) Shares Gap Up Following Analyst Upgrade

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report)’s stock price gapped up before the market opened on Wednesday after JPMorgan Chase & Co. raised their price target on the stock from $16.00 to $19.00. The stock had previously closed at $12.40, but opened at $13.19. JPMorgan Chase & Co. currently has an overweight rating on […] - 2025-07-18 02:20:52

Exchange Traded Concepts LLC Sells 5,196 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Exchange Traded Concepts LLC trimmed its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 32.5% in the first quarter, HoldingsChannel.com reports. The firm owned 10,814 shares of the company’s stock after selling 5,196 shares during the period. Exchange Traded Concepts LLC’s holdings in Replimune Group were worth $105,000 at the end of the […] - 2025-06-25 04:57:01

California State Teachers Retirement System Raises Stake in Replimune Group, Inc. (NASDAQ:REPL)

California State Teachers Retirement System boosted its position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 25.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 42,725 shares of the company’s stock after purchasing an additional 8,793 shares during the period. California State Teachers Retirement System’s holdings in Replimune Group were worth […] - 2025-06-12 04:52:49

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $796,000 Stake in Replimune Group, Inc. (NASDAQ:REPL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 19.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 65,762 shares of the company’s stock after selling 15,402 […] - 2025-06-11 04:38:55

Replimune Group, Inc. (NASDAQ:REPL) Receives $19.43 Consensus PT from Analysts

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has earned an average rating of “Buy” from the nine analysts that are presently covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price […] - 2025-06-03 03:07:12

Two Sigma Investments LP Buys 33,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Two Sigma Investments LP boosted its stake in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 18.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 212,586 shares of the company’s stock after acquiring an additional 33,346 shares during […] - 2025-06-01 06:37:00

Replimune Group, Inc. (NASDAQ:REPL) Stock Position Lifted by ProShare Advisors LLC

ProShare Advisors LLC grew its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 33.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,788 shares of the company’s stock after buying an additional 5,247 shares during the […] - 2025-06-01 05:46:47

Thursday's ETF Movers: XBI, URA

In trading on Thursday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 1.9% on the day. Components of that ETF showing particular strength include shares of Oric Pharmaceuticals, up about 33.8% and shares of Replimune Group, up about 9.6% on the day. And un - 2025-05-29 12:59:01

Two Sigma Advisers LP Lowers Position in Replimune Group, Inc. (NASDAQ:REPL)

Two Sigma Advisers LP decreased its position in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 9.6% during the fourth quarter, Holdings Channel reports. The fund owned 170,400 shares of the company’s stock after selling 18,000 shares during the period. Two Sigma Advisers LP’s holdings in Replimune Group were worth $2,064,000 as of […] - 2025-05-29 05:52:49

Nuveen Asset Management LLC Boosts Stake in Replimune Group, Inc. (NASDAQ:REPL)

Nuveen Asset Management LLC lifted its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 108.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 667,634 shares of the company’s stock after purchasing an additional 347,993 shares during the period. Nuveen Asset […] - 2025-05-29 04:56:55

Quantinno Capital Management LP Invests $127,000 in Replimune Group, Inc. (NASDAQ:REPL)

Quantinno Capital Management LP acquired a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,455 shares of the company’s stock, valued at approximately $127,000. Other institutional investors and […] - 2025-05-28 05:08:55

Investors Buy High Volume of Replimune Group Call Options (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) saw some unusual options trading on Thursday. Traders acquired 5,508 call options on the stock. This is an increase of approximately 652% compared to the average volume of 732 call options. Insider Buying and Selling at Replimune Group In other Replimune Group news, CAO Andrew Schwendenman sold […] - 2025-05-23 02:01:01

Hsbc Holdings PLC Buys Shares of 14,008 Replimune Group, Inc. (NASDAQ:REPL)

Hsbc Holdings PLC purchased a new position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) during the 4th quarter, HoldingsChannel reports. The firm purchased 14,008 shares of the company’s stock, valued at approximately $175,000. Several other hedge funds also recently modified their holdings of the business. Sterling Capital Management LLC increased its position in Replimune […] - 2025-05-12 04:56:47

Barclays PLC Raises Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)

Barclays PLC boosted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 5.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 167,329 shares of the company’s stock after acquiring an additional 8,838 shares during the quarter. […] - 2025-05-02 06:03:01

Invesco Ltd. Trims Stock Position in Replimune Group, Inc. (NASDAQ:REPL)

Invesco Ltd. cut its holdings in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 51.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 88,006 shares of the company’s stock after selling 92,952 shares during the period. Invesco Ltd.’s holdings in Replimune Group were worth $1,066,000 […] - 2025-05-02 04:30:49

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Wells Fargo & Company MN

Wells Fargo & Company MN boosted its holdings in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 102.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 77,371 shares of the company’s stock after acquiring an additional 39,121 shares during the period. Wells Fargo & Company MN’s holdings in Replimune Group were worth $937,000 as […] - 2025-04-30 05:14:51

Legal & General Group Plc Acquires 17,597 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Legal & General Group Plc lifted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 42.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,366 shares of the company’s stock after purchasing an additional 17,597 shares during the […] - 2025-04-29 04:50:50

Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $19.43

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has been given an average rating of “Buy” by the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target […] - 2025-04-14 02:59:04

Corebridge Financial Inc. Sells 2,284 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Corebridge Financial Inc. trimmed its holdings in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 7.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 30,267 shares of the company’s stock after selling 2,284 shares during the period. Corebridge Financial Inc.’s holdings in Replimune Group were worth $367,000 at the end of the most […] - 2025-04-10 05:33:06

Back to Listing

Disclaimer